A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/3/2018
Start Date:May 29, 2018
End Date:January 26, 2022
Contact:Clinical Trials Administrator
Email:clinicaltrials@regeneron.com
Phone:844-734-6643

Use our guide to learn which trials are right for you!

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

The primary objective of the study is to compare the objective response rate (ORR) of high
dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy
(SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line
treatment of patients with advanced squamous or non-squamous non-small cell lung cancer
(NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in <50% of
tumor cells.


Key Inclusion Criteria:

1. Patients with histologically or cytologically documented squamous or non-squamous
NSCLC who either have stage IIIb or stage IIIc disease who are not candidates for
treatment with definitive concurrent chemo-radiation or have stage IV disease.
Patients must have PD after receiving one prior line of chemotherapy treatment for
advanced NSCLC.

2. Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded
tumor tissue biopsy sample

3. Biopsy evaluable for expression of PD-L1 as determined by a PD-L1 Immunohistochemistry
(IHC) pharma diagnostic test (pharmDx) assay performed by a central laboratory

4. At least 1 radiographically measureable lesion by computed tomography (CT) per RECIST
1.1 criteria

5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

Key Exclusion Criteria:

1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime

2. Active or untreated brain metastases or spinal cord compression

3. Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene
mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene
receptor tyrosine kinase (ROS1) fusions

4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization

5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing
pneumonia), or active, noninfectious pneumonitis that required immune-suppressive
doses of glucocorticoids to assist with management, or of pneumonitis within the last
5 years

6. Ongoing or recent evidence of significant autoimmune disease that required treatment
with systemic immunosuppressive treatments, which may suggest a risk of immunerelated
treatment-emergent adverse events (irTEAEs)

7. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or
equivalent) within 14 days of randomization

Note: Other protocol defined Inclusion/Exclusion criteria apply.
We found this trial at
11
sites
Gettysburg, Pennsylvania 17325
?
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Bethesda, Maryland 20817
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bronx, New York
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Canton, Ohio 44708
?
mi
from
Canton, OH
Click here to add this to my saved trials
Los Angeles, California
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Massillon, Ohio 44646
?
mi
from
Massillon, OH
Click here to add this to my saved trials
Scarborough, Maine 04074
?
mi
from
Scarborough, ME
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Whittier, California 90602
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
?
mi
from
Wollongong,
Click here to add this to my saved trials